OTS - SHL Medical and Lifecore Biomedical enter co-marketing partnership agreement (part 2)
2023. October 17. 11:00
Zug, Switzerland, 17 October, 2023 (APA/OTS) -
About SHL Medical
As a world-leading solutions provider of advanced drug delivery
systems, SHL Medical is the partner of choice for many leading
pharma and biotech companies. Driven by its company purpose -
Enabling Patients' Independence - SHL Medical offers
patient-centric solutions for the design, development, and
manufacturing of autoinjectors, pen injectors, as well as
innovative specialty delivery systems for large-volume and
high-viscosity formulations. It also offers final assembly,
labeling, and packaging solutions for its drug delivery systems.
In response to the rising trend in home therapy, SHL Medical
has increased its developmental work in the digital healthcare
sector to help improve the drug delivery ecosystem.
Located across Switzerland, Taiwan, Sweden, and the US, SHL
Medical's global team of experts collaborate seamlessly as one team
in utilizing its comprehensive in-house manufacturing capabilities.
The company's solutions offer customization and optimization for
each project while proactively weaving sustainability-driven
measures into its designs and processes to contribute to a cleaner
earth. For additional information, visit www.shl-medical.com.
About Lifecore Biomedical
Lifecore Biomedical, Inc. is a fully integrated contract
development and manufacturing organization (CDMO) that offers
highly differentiated capabilities in the development, fill and
finish of complex sterile injectable pharmaceutical products in
syringes and vials. As a leading manufacturer of premium,
injectable grade Hyaluronic Acid, Lifecore brings more than 40
years of expertise as a partner for global and emerging
biopharmaceutical and biotechnology companies across multiple
therapeutic categories to bring their innovations to market. For
more information about the Company, visit Lifecore's website at
www.lifecore.com.
Media contact
Carl Gillblad
Communications and Marketing Operations
info@shl-medical.com
+41 41 368 00 00
Alliance Management contact
Alina Smotrova
Corporate Development
alliance@shl-medical.com
+41 41 368 00 00
Lifecore Investor Relations
Jeff Sonnek
jeff.sonnek@icrinc.com
(646) 277-1263
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements
regarding future events and future results, including the
anticipated business relationship between SHL and Lifecore, that
are subject to the safe harbor created under the Private Securities
Litigation Reform Act of 1995 and other safe harbors under the
Securities Act of 1933 and the Securities Exchange Act of 1934.
Words such as "anticipate", "estimate", "expect", "project",
"plan", "intend", "believe", "may", "might", "will", "should", "can
have", "likely" and similar expressions are used to identify
forward-looking statements. All forward-looking statements involve
certain risks and uncertainties that could cause actual results to
differ materially, including such factors among others, the nature
and requirements of the relationship between SHL and Lifecore, the
ability to achieve acceptance of Lifecore's new products in the
marketplace, and government regulations affecting the companies'
respective business. For additional information about factors that
could cause actual results to differ materially from those
described in the forward-looking statements, please refer to
Lifecore's filings with the Securities and Exchange Commission,
including the risk factors contained in our most recent Quarterly
Report on Form 10-Q and Annual Report on Form 10-K/A.
Forward-looking statements represent management's current
expectations and are inherently uncertain. Except as required by
law, neither company undertakes any obligation to update
forward-looking statements made to reflect subsequent events or
circumstances.
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók a
forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI által
szó szerint továbbított tartalomért minden esetben a beadó a
felelős.
© Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.